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group. Long-term ischemic treated rats (UR 0-E, UR 8-E) didLong-term protective effect of UR-12670 after warm renal
not develop chronic renal failure (GFR: UR 0-E, 2059 6 314;ischemia in uninephrectomized rats.
UR 8-E, 2410 6 208 ml/min). In these groups, glomerulosclerosisBackground. The phospholipid platelet-activating factor
(UR 0-E, 32.8 6 5.8; UR 8-E, 24.3 6 3.0%), tubulointerstitial(PAF) participates in the pathogenesis of renal ischemia/reper-
damage (tubulointerstitial score: UR 0-E, 2.1 6 0.5; UR 8-E,fusion injury, and in vitro, it induces synthesis of extracellular
1.9 6 0.3) and vascular myointimal hyperplasia were signifi-matrix proteins by mesangial and tubular epithelial cells. This
cantly lower than in the ischemic untreated group. By in situstudy investigated the long-term effects of the potent orally
hybridization, an increase of transforming growth factor-b1active PAF antagonist UR-12670 in warm ischemic uninephrec-
mRNA expression in glomerular and tubular cells was ob-tomized rats, which was given according to different therapeu-
served in ischemic untreated and ischemic treated UR 0-7 rats.tic schedules.
UR-12670 long-term treated rats showed a clear reduction ofMethods. Uninephrectomized male Sprague-Dawley rats
transforming growth factor-b1 mRNA-positive glomerular cells.were divided into five groups and were followed for 52 weeks:
Conclusion. The chronic administration of the PAF antago-rats without ischemia (SK); ischemic kidney for 60 minutes
nist UR-12670 attenuates the long-term effects of ischemia-(SIK); ischemic kidney and UR-12670 from 0 to the 7th day
reperfusion injury in uninephrectomized rats. The beneficial(UR 0-7); ischemic kidney and UR-12670 from day 0 to 52
effect of this agent, even when given beyond the initial ische-weeks (UR 0-E); and ischemic kidney and UR-12670 from day
mia/reperfusion injury, suggests that PAF plays a role in the8 to week 52 (UR 8-E). Two more groups (ischemic and UR
mechanisms of progression to late renal damage in this model.treated) served to evaluate the UR-12670–protective effect on
ischemic acute renal failure at one week.
Results. UR-12670 administration exerted functional and
morphological protection against post-ischemic acute renal Chronic transplant nephropathy, defined by progres-failure. The ischemic untreated (SIK) group developed pro-
sive functional deterioration associated with interstitialgressive proteinuria from week 12. The onset of proteinuria
fibrosis, tubular atrophy, and glomerulosclerosis, is thein ischemic UR-12670–treated groups was delayed to the 24th
week, and it was significantly lower than in SIK group through- leading cause of late renal allograft failure [1]. Risk fac-
out the study. Only SIK and ischemic-treated UR 0-7 rats tors for chronic transplant nephropathy have been con-
presented with chronic renal failure, as shown by creatinine, sidered as antigen-dependent (that is, immunological)
creatinine clearance, glomerular filtration rate (GFR), and re-
and antigen-independent (non-immunological) factors [2].nal plasma flow (GFR 52 weeks: SK, 2525 6 267; SIK, 992 6
The antigen-independent factor ischemia/reperfusion in-149; UR 0-7, 1551 6 385 ml/min). Kidneys from the short-term
jury and its clinical expression, delayed graft function,treated group (UR 0-7) showed a reduction of glomerulosclero-
sis (SK, 14.4 6 3.7; SIK, 75.7 6 7.7; UR 0-7, 41.5 6 8.5%) seem to exert a negative effect on graft survival [3, 4].
and vascular myointimal hyperplasia, but the tubulointerstitial In a model of warm renal ischemia combined with con-
damage (tubulointerstitial score: SK, 0.2 6 0.2; SIK, 4.4 6 0.5; tralateral nephrectomy, it has been demonstrated thatUR 0-7, 3.7 6 0.7) was similar to that in the ischemic untreated
ischemia/reperfusion injury induces long-term chronic
lesions that mimic those encountered in chronic trans-
plant nephropathy [5]. It has been proposed that whenKey words: chronic transplant nephropathy; platelet-activating factor;
reperfusion injury. only one kidney is engrafted, ischemia/reperfusion injury
causes a further reduction in total nephron mass thatReceived for publication December 1, 1998
is sufficient to accentuate glomerular injury. Survivingand in revised form April 15, 1999
Accepted for publication June 17, 1999 nephrons undergo hyperfiltration and hypertrophy, which
are associated with glomerular capillary hypertension, 1999 by the International Society of Nephrology
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synthesis of cytokines and growth factors, and extracellular acute renal failure. Two groups of animals were studied
according to the experimental procedure mentioned ear-matrix accumulation, which lead to glomerulosclerosis [6].
Thus, it is well known that in mesangial cells, mechanical lier in this article. Rats were followed for seven days and
on the first, second, third, and seventh day, 0.5 ml ofstress leads to matrix accumulation by means of the in-
duction of transforming growth factor-b1 (TGF-b1) [7], blood was obtained from the tail vein for serum creati-
nine measurement. Conventional histology was per-which is recognized as a key fibrogenic cytokine involved
in chronic transplant nephropathy [8]. formed on day 7. One of the groups was a control (ische-
mic, N 5 11), and the other received oral UR-12670Platelet-activating factor (PAF) is a potent phospho-
lipid mediator involved in acute inflammatory and im- daily (UR-treated, N 5 10).
For chronic experiments, animals were divided intomune responses [9]. Our group has previously shown
that treatment with PAF receptor antagonists protects five groups. Two were control groups: (a) the single kid-
ney group (SK), uninephrectomized rats with a left non-from warm renal [10] and cold [11] ischemia/reperfusion
injury in rat kidney, as well as from delayed graft function ischemic kidney (N 5 7), and (b) the single ischemic
kidney group (SIK), uninephrectomized rats with leftin cadaveric kidney transplantation [12]. However, the
role of PAF in the development of chronic nephropathy warm renal ischemia (N 5 12). (c) One was a short-
term treatment group of uninephrectomized rats withinduced by ischemia/reperfusion injury has not been pre-
viously studied. Interestingly, it has been recently de- left warm renal ischemia and UR-12670 administration
from day 0 until the seventh day post-ischemia and thenscribed that PAF induces the synthesis of extracellular
matrix proteins by mesangial [13] and tubular epithelial followed for 52 weeks (UR 0-7; N 5 12). Finally, two
were long-term UR-12670–treated groups: (d) uni-cells [14], suggesting a role for PAF in glomerulosclerosis
and interstitial fibrosis. nephrectomized rats with left warm renal ischemia and
UR-12670 administration from day 0 until the 52nd weekThe aim of this work was to evaluate, in the absence
of allorecognition, whether or not the administration of (UR 0-E; N 5 10), and uninephrectomized rats with left
warm renal ischemia in which drug administration wasthe oral PAF receptor antagonist UR-12670 could prevent
the development of chronic nephropathy induced by warm delayed for eight days after ischemia and then given until
the 52nd week (UR 8-E; N 5 12). Additional rats wererenal ischemia/reperfusion injury associated with nephron
mass reduction. We also evaluated whether this effect evaluated in the SK, SIK, and UR 0-E groups to allow
histological studies at 16 and 32 weeks (N 5 5 rats each).could be due to the protection against post-ischemic acute
renal failure, by giving a short course of UR-12670, or to Before the experiment and every four weeks after the
surgical procedure, all animals were placed in metabolicthe interference in PAF-mediated mechanisms potentially
involved in long-term tissue remodeling and fibrosis, by cages in order to collect a 24-hour urine sample. Animals
were weighed at the same intervals, and 0.5 ml of blooda chronic treatment with UR-12670.
from the tail vein was obtained.
METHODS Platelet-activating factor antagonist administration
Experimental design UR-12670 (Uriach Laboratories, Barcelona, Spain) is
a potent, orally active, and highly selective PAF receptorMale Sprague-Dawley rats (250 to 300 g body wt) were
used in this study. Animal care and interventions were antagonist that has been tested in several in vivo models
[15, 16]. The chemical name of UR-12670 is 1-[[1-(3,3-conducted in accordance with the guidelines of the Euro-
pean Community Committee on care and use of labora- diphenylpropanoyl)-4-piperidyl]methyl]-1-H-2-methyl-
imidazo [4,5-c] pyridine. It has a molecular weight oftory animals and good laboratory practice. After intra-
muscular anesthesia with a mixture of ketamine (75 mg/kg), 438.57 and is a hydrosoluble compound with a 100%
oral bioavailability [15].atropine (0.05 mg/kg), and diazepam (5 mg/kg), the ani-
mal was placed on a warming pad in order to maintain UR-12670 was administered intravenously at 10 mg/kg
five minutes before reperfusion and was later given orallybody temperature at the physiological range. A medial
laparotomy was performed, and left kidney normother- at 20 mg/kg by daily gavage.
mic ischemia was induced by renal pedicle occlusion for
Biochemical data60 minutes using a nontraumatic clamp. Simultaneously,
right nephrectomy was done, and finally, reperfusion was Proteinuria (mg/24 hr) was determined every four
weeks by the Ponceau method (Bayer Diagno´sticos, Ma-confirmed visually after clamp removal. Then the animals
were housed in a room kept at constant temperature with drid, Spain). Serum and urine creatinine (mg/dl) were
determined in the same intervals by Jaffe’s reaction ona 12-hour dark/12-hour light cycle. Rats had free access
to tap water and were fed a standard rodent diet. an autoanalyzer (Beckman Instruments, Palo Alto, CA,
USA), and creatinine clearance (ml/min/100 g body wt)Acute experiments were performed to assess the pro-
tective effect of oral UR-12670 against post-ischemic was calculated by the standard formula. At 12, 36, and
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52 weeks, total serum cholesterol was measured by an thenamine, and Masson trichrome. Light microscopic
sections were reviewed by a pathologist blinded to theenzymatic colorimetry method on an autoanalyzer (Beck-
man Instruments). treatment groups.
In acute experiments, sections were examined for sev-
Renal function studies eral parameters of tubulointerstitial damage, including
tubular dilation, tubular cell death and detachment, dys-At 52 weeks, animals were subjected to invasive func-
tional studies to assess glomerular filtration rate and trophic calcifications, and interstitial edema and acute
inflammation. For each case, a global estimation of therenal plasma flow and to measure arterial pressure. For
this purpose, rats were anesthetized again with an intra- tubular lesion was made and semiquantitatively graded
on a scale in which 0 was no abnormality, and 11, 21, 31,muscular mixture of ketamine/diazepam/atropine and
were placed on a heating pad to maintain body tempera- and 41 represented slight, mild, moderate, and severe
abnormalities, respectively.ture at a physiological range. Vascular polyethylene cath-
eters (PE-50) were implanted into the right carotid artery In chronic experiments, glomerulosclerosis was as-
sessed by examining at least 100 glomeruli in each kidneyand right jugular vein. Arterial catheter was used for
continuous monitoring of arterial pressure by means of and was expressed as the percentage of glomeruli pre-
senting either segmental or global sclerosis and hya-an electronic pressure transducer (Nihon Kohden Co.,
Germany) and for blood sampling. A venous catheter linosis. Tubular (atrophy and dilation) and interstitial
changes (fibrosis and mononuclear cell infiltrate), as wellwas used for the infusion of fluid and clearance markers.
The abdominal cavity was opened, and the ureter was as arterial myointimal hyperplasia, were graded from 0
to 31 (0, no changes; 11, changes affecting less thancannulated for the collection of urine with polyethylene
tubing (PE-10). Rats received a priming load of inulin one third of the sample; 21, changes affecting between
one and two thirds of the sample; 31, changes affecting(Polyfructosan; Laevosan, Linz, Austria) and paraamino-
hippuric acid (PAH; Merck, Darmstadt, Germany) (83 mg more than two thirds of the sample). In order to summa-
rize the tubulointerstitial changes in each animal, a tubu-of inulin and 5 mg of PAH) via the right jugular vein,
followed by a continuous infusion of a solution containing lointerstitial score was calculated by adding up the indi-
vidual value of the tubular damage, interstitial fibrosis,2% inulin and 0.6% PAH at a constant rate of 0.5 ml/
hr/100 g body wt. Urine collection was started after an and interstitial cell infiltrate.
equilibration period of 60 minutes. Three periods of 20
In situ transforming growth factor-b1 hybridizationminutes were established to determine inulin and PAH
clearances. At the midpoint of each period, 0.5 ml of Riboprobe for rat TGF-b1 (298 pb; Clontech Labora-
tories, Palo Alto, CA, USA) was prepared by the reversearterial blood was obtained. The inulin concentration in
plasma and urine was determined by the indole-3-acetic transcription polymerase chain reaction (RT-PCR) using
the 59-primer, 59-C TTC AGC TCC ACA GAG AAGacid (Merck) colorimetric assay. The PAH concentration
in plasma and urine was measured by the colorimetric AAC TGC-39, and 39-primer, 59-CAC GAT CAT GTT
GGA CAA CTG CTC C-39.Branson method. Glomerular filtration rate (GFR) and
renal plasma flow (RPF), measured as inulin and PAH Reverse transcription-PCR was performed with RNA
extracted from rat kidney serving as the template inclearances, respectively, were calculated by standard for-
mulas, and the final result was the mean of the three a Thermal Cycler (Perkin Elmer Corp., Norwalk, CT,
USA). Total RNA was obtained by the acid guanidine-values from each 20-minute period. It is well known
that in chronic renal disease the PAH extraction ratio thiocyanate-phenol-chloroform method [17], and 1 mg of
RNA was reverse transcribed to single-stranded cDNAis reduced, and thus, PAH clearance may underestimate
true RPF in this setting. The absolute values of PAH by incubation with reverse transcription mixture [5 mm
MgCl2, 10 mm Tris-HCl, pH 8.8, 50 mm KCl, 0.1% Tritonclearance should therefore be considered with the caveat
that a systematic error may exist. Nevertheless, PAH X-100, 1 mm dNTPs mixture, 50 ng oligo(dT) primer, 20
U RNasin, and 15 U reverse transcriptase from avianclearance was used as a comparative index of the putative
changes in RPF occurring with each experiment. At the myeloblastosis virus; all from Promega, Madison, WI,
USA]. Each PCR reaction containing 20 pmol of prim-end of the study, kidneys were perfused with a 48C iso-
tonic saline solution, removed, weighed, and processed ers, 0.5 mCi [a32P]dCTP (3000 Ci/mmol; Amersham, Ar-
lington Heights, IL, USA) and 3 U Taq DNA polymerasefor tissue studies.
was carried out under the following conditions: denatur-
Light microscopy ing at 948C for one minute, annealing at 608C for one
minute, and elongating at 728C for two minutes. The ex-Coronal 1 to 2 mm thick slices of the kidney were
fixed in 4% formaldehyde and embedded in paraffin, pression of glyceraldehyde-3-phosphate dehydrogenase
was used as internal control. The PCR product was ligatedand 3 to 4 mm thick tissue sections were stained with
hematoxylin and eosin, periodic acid-Schiff, silver me- into a PCR3 vector (Invitrogen, San Diego, CA, USA).
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Table 1. Renal functional profile (Creatinine, mmol/liter) andOrientation was confirmed by sequence and restriction
histologic evaluation of the acute tubulointerstitial lesions in
digestion. The templates were linearized with appro- Ischemic group (N 5 8; sixty minutes of left kidney warm ischemia,
contralateral nephrectomy and seven days of follow-up), and inpriate restriction enzymes, and then labeled antisense
the UR-treated group (N 5 8; the same experimental methodand sense cRNA probes were generated using T7 or SP6
plus the administration of daily oral UR-12670)
polymerases and digoxigenin-labeled uridine-triphos-
Ischemic UR-treated Pphate (Boehringer Mannheim, Mannheim, Germany) as
Serum creatininesubstrate according to the manufacturer’s instructions.
Basal 5464 5563 0.75For in situ hybridization, five randomly selected paraf-
First day 295616 308619 0.85
fin-embedded tissue sections per group were fixed in Second day 392634 288630 0.04
Third day 366644 195622 0.0041.5% paraformaldehyde-1.5% glutaraldehyde for 10 min-
Seventh day 79610 5962 0.08utes, washed and subsequently treated with 5 mm levami-
Histological damage 3.260.9 1.960.8 0.006
sole, 0.2 N HCl, and 25 mg/ml proteinase K in 0.1 m Tris
pH 7.8, 5 mm ethylenediaminetetraacetic acid (EDTA),
and 0.5% sodium dodecyl sulfate (SDS). Hybridization
was carried out at 428C with 0.4 ng/ml denatured digoxi-
lowed by a posteriori individual comparisons by Conno-genin-labeled riboprobes in hybridization solution [2 3
ver’s test. To analyze the correlation between proteinuriastandard saline citrate (SSC), 1 3 Denhardt’s, 0.1 m
and cholesterol, the simple regression analysis was used.sodium phosphate pH 6.5, 10% dextran sulfate, 40%
All P values were two tailed, and a P value of ,0.05deionized formamide, 24 mm Vanadyl Ribonuclease
was considered statistically significant. Data are pre-complex, and 0.5 mg/ml yeast tRNA]. After washing in
sented as mean 6 sem.2 3 SSC for five minutes and 0.2 3 SSC for three minutes,
sections were incubated with alkaline phosphatase conju-
gated antidigoxigenin antibody (1:750; Boehringer Mann- RESULTS
heim). Colorimetric detection of mRNA was performed Effect of UR-12670 on ischemic acute renal failure
with nitroblue tetrazolium and 5-bromo-4-chloro-3-indo-
This effect was analyzed in two groups of warm ische-lylphosphate in dark for 10 to 30 minutes. Negative con-
mic uninephrectomized rats (ischemic vs. UR-treatedtrols consisted of matched serial sections hybridized
groups) followed for seven days. The mortality rate inwithout RNA probe, with sense probe and sections pre-
this set of acute experiments was 3 out of 11 in thetreated with 25 mg/ml RNAse A for 20 to 30 minutes
ischemic group and 2 out of 10 in the UR-treated group.before hybridization with the corresponding antisense
Thus, eight animals per group fulfilled the seven-dayprobe.
follow-up. Twenty-four hours after ischemia, both groupsWe separately evaluated the mRNA TGF-b1 expres-
of rats displayed a similar degree of renal failure, assion in glomeruli and tubules. The total number of posi-
shown by the serum creatinine level (Table 1). Non-tive glomerular cells was counted in 30 glomeruli, and
treated rats showed a further increase in serum creatininethe mean value was used as a glomerular index of TGF-
that peaked on second day. Conversely, UR-12670–b1 (number of positive cells/glomerulus). The extent of
treated animals showed a progressive decline in serumtubular staining was assessed by means of a semiquanti-
creatinine on the second and third days. In fact, signifi-tative scale grading from 0 to 31.
cant differences between groups were observed on the
Statistical analysis second and third days. Seven days after ischemia, the
serum creatinine level returned to the basal value onlyTo compare the two groups, in acute experiments,
in UR-treated rats, although no significant differencesstatistical analysis was performed by the U-Mann Whit-
between both groups were observed.ney method. In long-term experiments, the chi-square
Concerning the histological evaluation, UR-treatedtest was used to compare the mortality ratio from acute
animals showed a significantly lower acute tubulointer-renal failure between the treated and nontreated groups.
stitial lesions induced by ischemia/reperfusion injuryTo compare more than two groups for proteinuria, serum
than ischemic animals (Table 1).creatinine, and creatinine clearance throughout the en-
tire follow-up period, statistical analysis was performed
Long-term effect of UR-12670 on renal functionalby the one-way analysis of variance (ANOVA) for re-
parameters after warm renal ischemia inpeated-measures method. To determine the origin of the
uninephrectomized ratsdifferences at any time point for these parameters, we
Considering all of the animals included for chronicused the one-way ANOVA for independent values fol-
follow-up studies, the mortality ratio from acute renallowed by Scheffe’s test. To compare histological and in
failure in the first week after ischemia was higher insitu TGF-b1 mRNA data, we used the nonparametric
Kruskal–Wallis test for between-subject analysis fol- rats that did not receive UR-12670 during this period
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Fig. 1. Effect of UR-12670 on proteinuria after
warm renal ischemia in uninephrectomized rats.
Symbols are: (▫; SK) single kidney, N 5 7; (d;
SIK) single ischemic kidney, N 5 9; (n; UR 0-7)
UR-12670 treated from 0 to 7 days, N 5 10; (h;
UR 8-E) UR-12670 treated from the 8th day until
52 weeks, N 5 8; (s; UR 0-E) UR-12670 treated
from 0 to 52 weeks, N 5 9. Uninephrectomized
ischemic rats (SIK) developed progressive pro-
teinuria from the 12th week (*P , 0.0001 SIK
vs. the other groups). The onset of proteinuria in
UR-12670–treated groups (UR 0-7, UR 0-E, and
UR 8-E) was delayed to the 24th week (**P 5
0.04, UR-12670 treated groups vs. SK). By the
one-way ANOVA for the repeated-measures
method, proteinuria was higher in the SIK group
than in the SK (P , 0.0001), UR 0-7 (P , 0.0001),
UR 0-E (P , 0.0001), and UR 8-E (P , 0.0001)
groups. Also, proteinuria was lower in the SK
group than in UR 0-7 (P 5 0.0006), UR 0-E (P ,
0.0001), and UR 8-E (P 5 0.02) groups. No sig-
nificant differences were seen among the three
UR-12670–treated groups.
(SIK16132152 and UR 8-E52, N 5 39) than in those animals sive arterial pressure among all of the experimental
groups, although potentially, anesthesia may have modi-to which the PAF antagonist was administered (UR 0-
752 and UR 0-E16132152, N 5 36, 35.9 vs. 13.9%, respec- fied this measure.
The total serum cholesterol showed a progressive in-tively, P 5 0.03). No further mortality was observed
during the follow-up periods in any of the groups. crease in the SIK group throughout the experiment, al-
though it remained unchanged in the rest of the groupsAfter recovering from acute renal failure, the number
of animals followed for 52 weeks was as follows: SK, (Table 2). A strongly positive correlation was seen be-
tween proteinuria in the 12th week and total serum cho-N 5 7; SIK, N 5 9; UR 0-7, N 5 10; UR 8-E, N 5 8;
UR 0-E, N 5 9. In the SIK group, proteinuria appeared lesterol in the 36th and 52nd weeks (P , 0.0001, r 2 5
0.5, and P , 0.0001, r 2 5 0.49, respectively).in the 12th week and showed a progressive increase
throughout the entire follow-up (Fig. 1). In UR-12670–
Effect of UR-12670 on long-term renal morphologytreated groups, proteinuria onset was delayed until the
after warm renal ischemia in uninephrectomized rats24th week, and it was significantly lower than in the
SIK group throughout the experiment. There were no When analyzing histological parameters, the SIK group
differences among the three treated groups at any time showed a significantly higher percentage of global glo-
merulosclerosis compared with SK (Table 3). All UR-point or along the entire follow-up. The SK group
showed only mild proteinuria, which was similar to that 12670–treated groups showed a lower percentage of
global glomerulosclerosis than SIK. In the UR 0-Ein UR-12670 treated groups until the 40th week.
The serum creatinine level in the SIK group showed group, these differences began in the 16th week, were
maintained in the 32nd week, and became statisticallya slight and progressive increase from the 28th week,
which became significantly higher beyond the 40th week significant in the 52nd week. When we extended the
glomerulosclerosis quantitation to not only global glo-when compared with SK and UR 8-E groups (Fig. 2).
From week 48, significant differences were found be- merular alterations but also focal and segmental glomer-
ulosclerosis, UR-12670–treated groups also showed sig-tween SIK and SK and both long-term treated groups
(UR 0-E and UR 8-E). In week 52, the SIK group showed nificantly lower percentages than SIK. Nevertheless,
when compared with SK, the UR 0-7 group displayedsevere renal failure with a mean serum creatinine of 2.2 6
0.7 mg/dl. As shown in Figure 2, only SIK and UR 0-7 significantly higher global and segmental glomeruloscle-
rosis. On the contrary, in both long-term treated groups,rats developed chronic renal failure. Conversely, both
long-term treated groups (UR 0-E and UR 8-E) showed glomerulosclerosis was not different from that in SK.
When tubular atrophy, interstitial cell infiltrate, andsimilar serum creatinine values to those of SK group.
Differences among groups in creatinine clearance through- fibrosis were analyzed, similar differences were observed
between groups. In 16th and 32nd week, kidneys fromout the study, as well as GFR and RPF values obtained
at the end of the experiment, paralleled those of serum the SIK group showed some degree of tubulointerstitial
injury, which was obvious in 52nd week (Fig. 3A). Ascreatinine (Table 2). No differences were found in inva-
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Fig. 2. Effect of UR-12670 on serum creatinine
after warm renal ischemia in uninephrectomized
rats. Symbols are: (n; SK) single kidney, N 5 7;
(d; SIK) single ischemic kidney, N 5 9; (n; UR
0-7) UR-12670 treated from 0 to 7 days, N 5 10;
(h; UR 8-E) UR-12670 treated from the 8th day
until 52 weeks, N 5 8; (s; UR 0-E) UR-12670
treated from 0 to 52 weeks, N 5 9. In the SIK
group, serum creatinine increased progressively
from the 28th week, and it became significantly
higher (§) beyond the 40th week when compared
with SK (P 5 0.04) and UR 8-E (P 5 0.04) groups.
From the 48th week, significant differences (*)
were found between the SIK and SK groups (P 5
0.03) and both long-term treated groups (UR 0-E,
P 5 0.04; UR 8-E, P 5 0.02). By the one-way
ANOVA for repeated-measures method, serum
creatinine was higher in the SIK group than in
the SK (P 5 0.0001), UR 0-E (P 5 0.0009) and
UR 8-E (P , 0.0001) groups, and was similar to
that in UR 0-7 group (P 5 0.3). Also, serum
creatinine was higher in UR 0-7 group than in
the UR 0-E (P 5 0.04), UR 8-E (P 5 0.008),
and SK (P 5 0.01) groups. No differences were
observed between the SK group and the UR 0-E
(P 5 0.5) and UR 8-E (P 5 0.9) groups.
Table 2. Total serum cholesterol, renal functional parameters, arterial pressure and kidney weight in all of the study groups
SK SIK UR 0-7 UR 0-E UR 8-E
Week N 5 7 N 5 9 N 5 10 N 5 9 N 5 8
Total serum cholesterol, mg/dl 12 7064 68 64 61 62 6162 6666
36 7365 17966a,b 9668 8865 7769
52 86610 18764a,b 10961 10861 10561
Creatinine clearance ll/min/100 g 16 287614 271 614 272 618 278610 300612
32 301615 278 615 283 639 308615 314610
52 259614 166630a,c 203632d 228615 270613
Glomerular filtration rate ll/min 52 25256267 9926149a,c 15516385d 20596314 24106208
Renal plasma flow ll/min 52 822361064 38156680a,c 534061285d 69516678 74196394
Arterial pressure mm Hg 52 11663 121 65 126 63 11864 12764
Kidney weight g 52 2.860.1 4.160.2a,c 3.460.4 3.260.1 2.960.2
Statistical analysis was performed by one-way analysis of variance followed by Scheffe´’s test. Abbreviations are: SK, single kidney; SIK, single ischemic kidney;
UR-07, short-term UR-12670 treated group from day 0 to day 7; UR 0-E, long-term UR-12670 treated group from day 8 to 52 weeks.
a P , 0.05 SIK vs. SK
b P , 0.05 SIK vs. UR 0–7, UR 0-E, UR 8-E
c P , 0.05 SIK vs. UR 0-E, UR 8-E
d P , 0.05 UR 0–7 vs. SK
shown in Table 3, kidneys from SIK group exhibited a ingly, kidneys from UR-12670–treated groups, in short
and long-term schedules, had significantly fewer vascularhigher level of tubulointerstitial damage than kidneys
from the SK group, in which only minimal changes were lesions than kidneys from the SIK group.
seen. When kidneys from the SIK group were compared
Effect of UR-12670 on renal TGF-b1with the UR 0-7 group (Fig. 3B), no significant differ-
mRNA expressionences were found (tubulointerstitial score: SIK, 4.4 6
0.5; UR 0-7, 3.7 6 0.7, P 5 0.35). Conversely, both long- The SIK group showed higher TGF-b1 mRNA expres-
sion in glomerular (Figs. 3D and 4A) and tubular (Figs.term treatment groups (Fig. 3C) showed significantly
lower tubular atrophy, interstitial infiltrate, and fibrosis 3D and 4B) cells than the SK group. It is noteworthy
that tubular staining disclosed focal distribution (Fig.than the SIK group (Table 3).
Kidneys from the SK group showed no vascular abnor- 3D). When analyzing UR-12670–treated groups, the
TGF-b1 mRNA glomerular index was similar in UR 0-7malities throughout the follow-up. On the contrary, in
the 32nd week and especially in the 52nd week, kidneys and SIK (Figs. 3E and 4A) animals. In both long-term
UR-12670–treated groups (Fig. 3F), the number of posi-from the SIK group had vascular myointimal hyperplasia
with luminal narrowing of the affected vessels. Interest- tive glomerular cells was significantly lower than in the
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Table 3. Glomerulosclerosis, vascular myointimal hyperplasia and chronic tubulointerstitial parameters at 16, 32 and 52 weeks
Week SK SIK UR 0–7 UR 0-E UR 8-E
Global glomerulosclerosis % 16 1.060.6 4.9 61.5a 2.760.9
32 2.461.0 12.663.1a 5.763.2
52 1.760.5 36.168.3a,b 12.463.1 14.764.5 9.9 62.9
Global 1 segmental glomerulosclerosis % 52 14.463.7 75.7 67.7a,b 41.568.5c 32.865.8 24.3 63.0
Tubular atrophy 16 060 0.560.3 0.7 60.2
32 0.260.2 1.2 60.4a 0.660.2
52 0.260.2 1.8 60.2a,d 1.560.3 0.960.2 0.9 60.1
Fibrosis 16 060 0.360.3 0 60
32 060 0.460.2 0 60
52 060 1.160.2a,d 0.860.3e 0.560.2 0.3 60.2
Interstitial infiltrate 16 060 1.060.4a 0.760.2
32 060 1.060.3a 0.860.2
52 060 1.560.2a,d 1.360.2e,f 0.760.2 0.7 60.2
Tubulointerstitial score 16 060 1.860.8a 1.560.5
32 0.260.2 2.6 60.8a 1.460.4
52 0.260.2 4.4 60.5a,d 3.760.7e 2.160.5 1.9 60.3
Vascular myointimal hyperplasia 16 060 0 60 0 60
32 060 1.060.2a 0.460.3
52 060 1.260.1a,b 0.760.2 0.560.2 0.2 60.2
Abbreviations are in Table 2. The number of animals at 16 and 32 weeks was 5 in each experimental group (SK, SIK and UR 0-E). At 52 weeks: SK, N 5 7;
SIK, N 5 9; UR 0–7, N 5 10; UR 8-E, N 5 8; UR 0-E, N 5 9. Statistical analysis was performed by Kruskall-Wallis test and a posteriori individual comparisons by
Connover’s test.
aP , 0.05 SIK vs. SK
bP , 0.05 SIK vs. UR 0–7, UR 0-E, UR 8-E
cP , 0.05 UR 0–7 vs. SK
dP , 0.05 SIK vs. UR 0-E, UR 8-E
eP , 0.05 UR 0–7 vs. UR 8-E
fP , 0.05 UR 0–7 vs. UR 0-E
SIK group and similar to the SK group (Fig. 4A). In this context, it has been proposed that further loss of
nephrons because of initial ischemia may be critical [5,contrast, there were no significant differences in tubular
19], and thus, these kidneys develop chronic renal dys-staining between all treated groups and kidneys from
function by mechanisms described in the so-called hyper-the SIK group (Fig. 4E).
filtration theory [20, 21]. Thus, models of a single kidney
subjected to either warm or cold ischemia in uninephrec-
DISCUSSION tomized rats are valuable tools to explore antigen-inde-
In this work, we have shown that the administration pendent mechanisms of chronic transplant nephropathy
of the PAF receptor antagonist UR-12670 attenuates [4, 22, 23].
the long-term effects of ischemia/reperfusion injury in The expression pattern of cellular and molecular medi-
uninephrectomized rats. Animals chronically receiving ators in the early [22–24] and late [5] stages after ische-
UR-12670 have a delay in the onset and a reduction of mia/reperfusion injury has been previously reported.
proteinuria, do not develop chronic renal failure, and Several groups, including ours [10, 11, 25], have recently
have a decrease in the glomerular TGF-b1 mRNA ex- described that PAF also plays a key role in the regulatory
pression, as well as in the glomerulosclerosis and intersti- mechanisms of post-ischemic acute renal failure. In pre-
tial fibrosis. This study also shows that protection from vious studies, we showed that a single intravenous injec-
post-ischemic acute renal failure by a PAF antagonist tion of the PAF receptor antagonist, BN 52021, pre-
delays and reduces proteinuria, but does not completely vented renal dysfunction and histological damage caused
hamper the appearance of chronic renal failure and inter- by warm ischemia. Furthermore, in a model of cold ische-
stitial fibrosis. The beneficial effect of UR-12670, even mia, BN 52021 was able to overcome the functional dam-
when given beyond the first week, that is, after the initial age induced by PAF [11]. Because UR-12670 has not
ischemic injury has already occurred, strongly suggests been tested in warm renal ischemia, we started our study
that PAF plays a role in the mechanisms of progression by analyzing the protection of renal ischemia/reperfusion
of chronic renal damage. injury by this agent. Results from the acute experiments
There is some evidence suggesting that the nonimmu- using UR-12670 extend the observations mentioned in
nological factor ischemia/reperfusion injury may be in- this section, showing that PAF receptor blockade attenu-
volved in the pathogenesis of chronic transplant nephropa- ates the renal dysfunction and, even more interesting,
thy [4, 18]. In renal transplantation, a 50% nephron mass the histological lesions induced by warm ischemia.
The long-term impact of these initial functional andis usually offered because only one kidney is grafted. In
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Fig. 3. Silver methenamine staining (A–C ) and in situ hybridization of TGF-b1 mRNA (D–F ) in kidneys from SIK, UR 0-7, and UR 0-E groups
harvested at 52 weeks. (A) A representative kidney section from SIK group showing glomerulosclerosis, severe interstitial cell infiltrate, and
tubular atrophy and dilation (3200). (B) Tubulointerstitial lesions are evident in kidneys from UR 0-7 group. One glomerulus shows focal and
segmental glomerulosclerosis (arrow; 3200). (C) Mild tubulointerstitial lesions and glomerulosclerosis were observed in UR-12670 long-term
treated groups, as shown by this representative kidney section from the UR 0-E group (3200). (D) Kidney from a SIK rat showing groups of
tubules with strong cytoplasmic TGF-b1 mRNA expression. Several positive glomerular cells are also seen (3400). (E) UR 0-7 kidney section
showing also several glomerular and tubular positive TGF-b1 mRNA cellular staining (3200.) (F) Kidney from the UR 0-E group showing focal
tubular TGF-b1 mRNA expression. Glomerular TGF-b1 mRNA staining is weak and scarce in the long-term treated groups (3200).
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mentioned studies, in which 45 minutes of renal ischemia
were employed [26, 27]. Thus, treating only the initial
ischemia/reperfusion injury with UR-12670 does not
seem to be sufficient to completely prevent the progres-
sion to chronic organ dysfunction, especially after a se-
vere renal ischemic injury.
We designed two other groups in order to ascertain
whether PAF is involved in the progression to chronic
renal damage after ischemia/reperfusion injury in uni-
nephrectomized rats. According to the renal protective
effect of UR-12670, we can assume that acute renal le-
sions secondary to ischemia/reperfusion injury could
probably be higher in the UR 8-E group than in the UR
0-E group. However, the survivors from both long-term
UR-12670–treated groups showed similar attenuation of
chronic renal dysfunction and renal lesions. These find-
ings suggest that after ischemia/reperfusion injury and
apart from the severity of acute renal failure, long-term
blockade of PAF receptor interferes with the mecha-
nisms involved in the progression of chronic nephropa-
thy. This is clearly supported by the lower proteinuria,
Fig. 4. Effect of UR-12670 on glomerular (A) and tubular (B) TGF- the absence of renal failure, and the low glomerulosclero-
b1 mRNA expression. Five randomly selected kidney samples per group sis, tubulointerstitial chronic damage, and vascular myo-
were analyzed. (A) In both UR-12670 long-term treated groups (UR
intimal hyperplasia in long-term UR-12670–treated ani-0-E and UR 8-E), glomerular cell TGF-b1 mRNA expression was
significantly lower (*P , 0.03) than in the SIK group and the short- mals in comparison to the nontreated ischemic rats.
term treated group (UR 0-7) and was similar to the SK group (P 5 Platelet-activating factor has classically been involved
0.9). (B) Tubular TGF-b1 mRNA expression was higher in the SIK
as a key mediator in both the vasomotor and the in-group than in the SK group (**P 5 0.03) and was similar to that in all
UR-12670 treated groups. No differences were observed between UR flammatory responses occurring early in postrenal ische-
0-7, UR 0-E, and UR 8-E groups. mia [10, 11, 28, 29]. Our results suggest that PAF could
also be considered as an important mediator of renal
tissue matrix remodeling following ischemia in nephron
mass ablation. The pathogenic mechanisms that lead to
morphological benefits was analyzed by following animals chronic organ dysfunction in this situation remain par-
for 52 weeks. Notably, short treatment with UR-12670 tially unknown, although ischemic organs are progres-
delayed and reduced proteinuria and glomerulosclerosis, sively infiltrated by T cells and macrophages, mainly
similarly to what occurred when prolonged long-term located in glomeruli and around vessels [5, 22, 23]. The
treatment was used; however, these UR 0-7 treated ische- presence of these cell populations is associated with the
mic rats disclosed late renal failure and severe chronic release of biological mediators, such as interleukin-1,
tubulointerstitial lesions. These findings suggest that pro- tumor necrosis factor-a, TGF-b1, endothelin-1, and the
tection of post-ischemic acute renal failure by UR-12670 induction of nitric oxide synthase. Cells, cytokines, and
only partially hindered the progression toward chronic chemoattractants, coupled with adhesion molecules, ini-
nephropathy in this model. Other authors, treating post- tiate a cascade that may ultimately stimulate prolifera-
ischemic acute renal failure either by a soluble form of tion of arterial smooth muscle cells, glomerular mesan-
P-selectin glycoprotein ligand [26] or by blocking the B7 gial cells, and fibroblasts [5, 30]. In various models of
costimulatory pathway with CTLA4Ig [27], found more chronic nephropathy, it has been demonstrated that in-
evident long-term protection against chronic renal in- filtrating T cells and macrophages [31] as well as the intrin-
jury. A possible explanation may be that, in contrast to sic glomerular cells are sources of PAF [13, 14, 31, 32].
P-selectin glycoprotein ligand and CTLA4Ig treatment, In addition, several mediators, including endothelin-1,
which fully protected kidneys from organ dysfunction induce the release of PAF by mesangial cells [33].
and leukocyte infiltration after ischemia/reperfusion in- Recent studies have shown that TGF-b1 is a key fibro-
jury, UR-12670–treated kidneys were only partially pro- genic cytokine involved in the pathogenesis of chronic
tected possibly because of the more prolonged warm nephropathy after ischemia and renal mass reduction
ischemia we used. Moreover, ischemic untreated rats [5, 27]. In addition, in experimental models of chronic
(SIK) developed chronic renal failure and achieved a renal injury, an overproduction of TGF-b1 has been
linked to the development of glomerulosclerosis [34, 35].fivefold higher proteinuria than rats in the previously
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Our results extend these observations because the ische- tion of extracellular matrix components by tubular cells
and up-regulating inflammatory and vasoactive genesmic kidneys showed a higher degree of TGF-b1 mRNA
expression, both in glomerular and tubular cells, than such as monocyte chemoattractant protein-1 (MCP-1),
RANTES, and endothelin-1 (ET-1) [41, 42]. Moreover,nonischemic kidneys. In cultured mesangial cells, endog-
enous TGF-b1 has been identified as an important medi- recently it has been reported that proteinuria is the best
predictor of progression toward chronic renal failure inator of the stimulatory effect of PAF on matrix protein
synthesis [13], suggesting that PAF contributes to the nondiabetic patients [43]. An enhanced glomerular PAF
production has been documented in some proteinuricaccumulation of mesangial matrix that occurs during glo-
merulosclerosis. According to these in vitro observations, nephropathies, and in these studies PAF receptor antag-
onists had an antiproteinuric effect [40]. Therefore, thein long-term UR-12670–treated kidneys, we found a
clear reduction in the glomerulosclerosis as well as in delayed and moderate proteinuria in UR-12670–treated
rats seen in our model could be related either to thethe number of mRNA TGF-b1-positive glomerular cells
down to the level disclosed in the nonischemic uni- initial reduction of the extent of acute renal lesions
caused by ischemia/reperfusion injury (UR 0-7 and URnephrectomized rats. Our findings suggest that the con-
tribution of PAF to glomerulosclerosis was mediated, at 0-E groups) or to the described antiproteinuric effect of
least in part, by the induction of TGF-b1 in glomerular PAF receptor blockade in the long term administration
cells. On the other hand, our results show that there were (UR 0-E and UR 8-E groups).
no significant differences in glomerulosclerosis between In summary, our results provide evidence that in the
ischemic-treated UR 0-7 group and both long-term UR- model of warm renal ischemia and mass reduction, long-
12670 ischemic-treated groups. However, in contrast to term administration of the PAF receptor antagonist UR-
long-term–treated groups, the UR 0-7 group displayed 12670 may be useful for the prevention of late renal
a significantly higher global and segmental glomerulo- dysfunction and morphological lesions. Moreover, our
sclerosis than nonischemic uninephrectomized rats. Nev- data further strengthen the idea that PAF plays a role in
ertheless, there were apparently discordant results be- the mechanisms of progression of chronic renal damage.
tween the high glomerular TGF-b1 gene expression and
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